NDAORALCAPSULEPriority Review
Approved
Nov 2020
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
7
Mechanism of Action
Farnesyltransferase Inhibitors
Pharmacologic Class:
Farnesyltransferase Inhibitor
Clinical Trials (5)
Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
Started Aug 2009
85 enrolled
Progeria
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer
Started Aug 2009
27 enrolled
Breast Cancer
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
Started Jun 2007
5 enrolled
Prostate CancerBreast CancerOvarian Cancer+2 more
Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)
Started May 2005
47 enrolled
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicMyelodysplasia+1 more
Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)
Started Dec 2003
110 enrolled
Breast Cancer
Loss of Exclusivity
LOE Date
Jul 26, 2029
41 months away
Patent Expiry
Jul 26, 2029
Exclusivity Expiry
Nov 20, 2027
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7838531 | Jul 26, 2029 | U-3070 |